Aspire Biopharma Holdings (ASBP) Revenue (2025 - 2026)

Aspire Biopharma Holdings' (ASBP) quarterly Revenue came in at $28353.0 in Q1 2026, up 565.41% on a QoQ basis from $4261.0 in Q4 2025.

Aspire Biopharma Holdings (ASBP) Revenue (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has 2 years of Revenue data on file, last reported at $28353.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.51 Bn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Aspire Biopharma Holdings 1.21 Mn -619,284.29 5,750.00 28,353.00

Historic Data

Download Data
DateValue
Mar 31, 2026 28,353.00
Dec 31, 2025 4,261.00
Sep 30, 2025 1,941.00